Login to Your Account

Poxel Adds $17M in Series B for Diabetes Drug Imeglimin

By Nuala Moran
Staff Writer

Wednesday, December 26, 2012

Poxel SA raised €13 million (US$17.3 million) in a Series B round that is intended to see its lead Type II diabetes treatment, imeglimin, through Phase IIb and into the arms of a commercialization partner.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription